PRECISION EPIGENOMICS®

You save others' lives.

We can help save yours.

Firefighter occupational cancer is

the top cause of line-of-duty deaths.

Firefighters are **up to twice as likely to get some cancer** than the average American.

EPISEEK™ will help get more firefighters tested with our quick, accurate, and affordable **cancer screening.**

EPISEEK®

PRECISION EPIGENOMICS

EPISEEK is the only test to screen for **all of the top 10 cancers,** including brain.

EPISEEK™ is a multi-cancer early detection test that screens for more than **60 types of cancer,** including...

testicular cancer
2.02 *times the risk*

skin cancer
1.39 *times greater risk*

prostate cancer
1.28 *times greater risk*

mesothelioma
2.0 *times greater risk*

melanoma
1.31 *times greater risk*

colon cancer
1.21 *times great risk*

multiple myeloma
1.53 *times greater risk*

brain cancer
1.31 *times greater risk*

leukemia
1.14 *times greater risk*

lymphoma
1.51 *times greater risk*

PRECISION EPIGENOMICS

The **EPISEEK™** test detects some cancers **more reliably than others**



PRECISION EPIGENOMICS

Detailed **EPISEEK™** Screening Performance



- Target Cancers were selected as poor five-year survival (aggressive) and no widely used available screening method
- All Cancers group includes 60+ types including slowly growing and less fatal cancers such as thyroid
- **EPISEEK™** Shows high sensitivity for early aggressive cancer types that currently have no widely used screening approach
- The result in this figure are incidence adjusted estimates generated using results from testing 281 plasma samples from cancer patients across cancer types and stages, a generalized linear model, and SEER cancer incidence data.

Competitive **in-market MCED landscape**

EPISEEK™ is faster, cheaper, and comparable if not superior to Competitor, the only other available molecular MCED test in the USA.

FEATURES	PRECISION EPIGENOMICS®	Competitor
Technology	qPCR simplicity	NGS complexity
Turn Around Time (TAT)*	5 days	10 days
Specificity	99.5%	99.5%
*Sensitivity, Brain and Spine	43% (3/7)	0% (0/6)
*Sensitivity, Lung, Stage I	59% (10/17)	22% (21/96)
*Sensitivity, Bladder, Stage I	45% (5/11)	35% (8/23)
*Sensitivity, Uterus, Stage I	56% (9/16)	17% (20/120)
PPV#/NPV	65%/99.5%	44%/99.4%
Suggested Price/test	$699	$950

*** Observed Sensitivity**
 # Positive Predictive Value (PPV) for mammography and breast cancer is ~5%

Competitive **MCED Landscape**



Competitive **MCED Landscape**

EPISEEK™ (Incidence Adjusted) vs **Competitor** (Observed)



PRECISION EPIGENOMICS

RESULTS

66.6%
Observed Sensitivity:
(187 / 281)

99.5%
Observed Specificity:
(200 / 201)

*Targeted Cancers: Bladder, Esophagus, Head and Neck, Liver, Lung, Pancreas, Stomach, Uterus



54% Incidence Adjusted Sensitivity (All Cancers)

75% Incidence Adjusted Sensitivity (Target Cancers*)

64.9% Positive Predictive Value

99.5% Negative Predictive Value

Precision Epigenomics' liquid biopsy test,

EPISEEK™ is a blood-based screening tool designed to detect circulating tumor DNA (ctDNA)—DNA shed by tumors.

EPISEEK focuses on cancer-specific, abnormally methylated cell-free DNA, **using a patented set of biomarkers unique to cancer cells and absent in normal cells.**

With advanced software for **analyzing epigenomic modifications,**

EPISEEK™ offers a cost-effective, precise, and minimally invasive approach that may detect cancer earlier and is more accessible than traditional tissue biopsies.

EPISEEK™ screens for all major cancer types, including those without existing early detection or screening methods.

By examining tumor-specific DNA methylation patterns, this liquid biopsy provides reliable cancer screening.*



EPISEEK is faster, is less expensive, and detects brain cancer, unlike other tests on the market.

Who is EPISEEK® for?

The EPISEEK test is recommended for

- ***Firefighters** of any age*
- ***Others with an elevated risk of cancer***
- ***Any individuals aged 45 or older***

The test is not recommended for

- Individuals who are pregnant
- Individuals aged 21 years or younger
- Individuals undergoing active cancer treatment or those with an active known malignancy

Chiefs and firefighters, contact us today
to add EPISEEK to your cancer screening regimen, and receive a special rate for first responders!

PRECISION EPIGENOMICS®

How It Works

More than just an early cancer detection test
it's peace of mind!

Fill out the form
on the website to have a kit sent to you

Get blood drawn
and ship the kit to the lab

Receive results
directly from your provider

It's that easy!

+ Literature Supporting EPISEEK

Pham TH, Routh J, Oshiro MM, et al. "Analytical validation of EPISEEK, an epigenomic blood-based assay for multicancer detection" *J Clin Oncol*. 2025;43(16_suppl):3144.

Routh J., Bernert R., Fortin Ensign S. "Evaluation of a multicancer early detection test for identifying circulating tumor DNA in plasma of glioblastoma patients using bisulfite conversion and methylation-specific PCR." *The Journal of Molecular Diagnostics* 2024 Nov;26(11):S1525-1578

Vrba L, Futscher B, et al. "Sentinel-10 – a new multi-cancer early detection test." *The Journal of Molecular Diagnostics* 2022 Nov;22(10):S155-173.

Vrba L., Futscher BW, Oshiro M., et al. "Liquid biopsy, using a novel DNA methylation signature, distinguishes pancreatic adenocarcinoma from benign pancreatic disease." *Clin Epigenetics*. 2022;14(1):28. Published 2022 Feb 22.

Vrba L., Oshiro MM, Kim SS, et al. "DNA methylation biomarkers discovered in silico detect cancer in liquid biopsies from non-small cell lung cancer patients." *Epigenetics*. 2020;15(4):419-430.

Vrba L., Futscher BW. "A suite of DNA methylation markers that can detect most common human cancers." *Epigenetics*. 2018;13(1):61-72.

PRECISION EPIGENOMICS


Ask about the Firefighter's Multi-Cancer Detection Test
At Precision Epigenomics, we're dedicated to bringing you the latest in healthcare technology to help detect even the most serious cancers at their earliest stages
so you can focus on
what matters most.
PRECISION EPIGENOMICS

Contact us

about ordering the Firefighters' Multi-Cancer Detection Test today!

Have questions? Let's talk.

Info@medhometesting.com

This test may be eligible for purchase with HSA/FSA funds.

PRECISION EPIGENOMICS